 |
|
 |
| |
 |
|
|
| |
American Society of Clinical Oncology (ASCO) 2010 Annual Meeting
6/4/2010
Type: Physician
Location: Chicago, IL
The 2010 ASCO Physician Conference is being held on June 4th to June 8th, 2010 in Chicago, IL. The American Society of Clinical Oncology (ASCO), www.asco.org is an annual Conference for Hematologists and Oncologists that offer invaluable benefits, including up-to-date research, therapies, and networking events that allowed physicians to connect with colleagues and interact with leaders in the field in all branches of hematology and oncology, mainly on a clinical level. Overall, the Conference is a great success for the Bing Center for WM. Our six (6) abstract submissions have been accepted and will be presented to over 20,000 medical peers from around the world.
For any questions about the abstracts, please feel free to contact Christopher Patterson at cpatterson1@partners.org and we will be happy to direct you to the author of the presentation.
Clinical characteristics and treatment outcome of disease related peripheral neuropathy in Waldenstrom’s Macroglobulinemia (WM). Treon SP, Hanzis C, Ioakimidis L, Patterson CJ, Hunter ZR, Sheehy PS, Manning RJ. Bing Center for Waldenstrom’s macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom’s Macroglobulinemia (WM) who respond to a rituximab containing regimen. Leukothea Ioakimidis, Christina Hanzis, Robert J. Manning, Christopher J. Patterson, Jacob D. Soumerai, Zachary R. Hunter, Philip S. Brodsky, Patricia Sheehy, Barry Turnbull, Steven P. Treon, Dana Farber Cancer Institute, BioBridges, Harvard Medical School, and Boston MA, USA.
The attainment of CR/VGPR is associated with significantly longer progression free survival in rituximab naïve WM patients undergoing rituximab based therapy, and is predicted by polymorphisms in FcgRIIIA-158. Zachary R. Hunter, Guang Yang, Leukothea Ioakimidis, Christina Hanzis, Robert J. Manning, Christopher J. Patterson, Patricia Sheehy, Ping Gong, Sigitas J. Verselis, Edward A. Fox, Lian Xu, Barry Turnbull, and Steven P. Treon. Bing Center for Waldenstrom’s Macroglobulinemia, Dana Farber Cancer Institute; Harvard Medical School; Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, and BioBridges, Inc., Boston MA, USA.
The CD20 directed monoclonal antibody GA101 demonstrates more robust activity relative to Rituximab in Waldenstrom’s Macroglobulinemia (WM), and may be particularly applicable to those patients expressing FcgRIIIA-158 F/F. Yang G, Gong P, Xu L, Hunter ZR, Zhou Y, Liu X, Cao Y, Ciccarelli B, Patterson CJ, Treon SP.
The NEDD8-specific inhibitor MLN 4924 exhibits activity in multiple myeloma and Waldenström’s Macroglobulinemia and modulates miRNA expression. Douglas W. McMillin, Zachary R. Hunter, Jake Delmore, Peter Smith, Ann Birner, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades, and Steven P. Treon Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bing Center for Waldenström Macroglobulinemia Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Millenium Pharmaceuticals, the Takada Oncology Company, Cambridge, MA, USA.
Phase II Study of Alemtuzumab in Lymphoplasmacytic Lymphoma (Waldenstrom’s Macroglobulinemia): Long Term Follow-Up of WMCTG trial 02-079. Soumerai JD, Hunter ZR, Boxer M, Kahl B, Ioakimidis L, Patterson CJ, Treon SP.
<< Back
|
|
| |
|
|
